These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28363320)

  • 21. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
    Zhu Y; Evans EA; Mooney LJ; Saxon AJ; Kelleghan A; Yoo C; Hser YI
    J Neuroimmune Pharmacol; 2018 Dec; 13(4):488-497. PubMed ID: 30094695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Participant characteristics and buprenorphine dose.
    Hillhouse M; Canamar CP; Doraimani G; Thomas C; Hasson A; Ling W
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):453-9. PubMed ID: 21854290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
    González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
    Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive Behavioral Therapy Improves Treatment Outcomes for Prescription Opioid Users in Primary Care Buprenorphine Treatment.
    Moore BA; Fiellin DA; Cutter CJ; Buono FD; Barry DT; Fiellin LE; O'Connor PG; Schottenfeld RS
    J Subst Abuse Treat; 2016 Dec; 71():54-57. PubMed ID: 27776678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-Year Follow-Up of Heroin-Dependent Adolescents Treated with Buprenorfine/Naloxone for the First Time in a Substance Treatment Unit.
    Mutlu C; Demirci AC; Yalcin O; Kilicoglu AG; Topal M; Karacetin G
    J Subst Abuse Treat; 2016 Aug; 67():1-8. PubMed ID: 27296655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial.
    Marsden J; Stillwell G; Hellier J; Brown AM; Byford S; Kelleher M; Kelly J; Murphy C; Shearer J; Mitcheson L
    Contemp Clin Trials; 2017 Feb; 53():36-43. PubMed ID: 27940188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.
    Alexandridis AA; Dasgupta N; Ringwalt CL; Rosamond WD; Chelminski PR; Marshall SW
    PLoS One; 2020; 15(1):e0227350. PubMed ID: 31923197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
    Hoffman K; Peyton ML; Sumner M
    J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.
    Murray JP; Pucci G; Weyer G; Ari M; Dickson S; Kerins A
    Addict Sci Clin Pract; 2023 Jun; 18(1):38. PubMed ID: 37264449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Surgeon Saved My Life: A Story of Addiction.
    Warner NS
    Mayo Clin Proc; 2020 Apr; 95(4):658-659. PubMed ID: 32247340
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients' Perceptions and Attitudes.
    Young GJ; Hasan MM; Young LD; Noor-E-Alam M
    Subst Use Misuse; 2023; 58(4):512-519. PubMed ID: 36762464
    [No Abstract]   [Full Text] [Related]  

  • 37. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF; Black RA; Severtson SG; Dart RC; Green JL
    J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
    Caldiero RM; Parran TV; Adelman CL; Piche B
    Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 40. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.